NCT06226662 - Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

October 31, 2027

Study Completion Date

September 30, 2028

Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

DRUG

NM8074

NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.

DRUG

Placebo

Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.